{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:46:48Z","timestamp":1791956808934,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01441-1","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:23:12Z","timestamp":1789644192000},"page":"3151-3167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Prediction of Carbapenem Resistance in Gram-Negative Organisms at Culture Ordering from Routinely Collected Hospital Data: Temporal and External Validation of ORDER-CARB"],"prefix":"10.1007","volume":"15","author":[{"given":"Emmanuel Pio","family":"Pastore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"10325","key":"1441_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"1441_CR2","unstructured":"World Health Organization. Antimicrobial resistance. Fact sheet. Updated 16 July 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance. Accessed 22 Jul 2026."},{"issue":"10","key":"1441_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3201\/eid1710.110655","volume":"17","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791\u20138. https:\/\/doi.org\/10.3201\/eid1710.110655.","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"1441_CR4","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41591-019-0503-6","volume":"25","author":"I Yelin","year":"2019","unstructured":"Yelin I, Snitser O, Novich G, et al. Personal clinical history predicts antibiotic resistance of urinary tract infections. Nat Med. 2019;25(7):1143\u201352. https:\/\/doi.org\/10.1038\/s41591-019-0503-6.","journal-title":"Nat Med"},{"issue":"1","key":"1441_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s44259-023-00015-2","volume":"1","author":"J Yang","year":"2023","unstructured":"Yang J, Eyre DW, Lu L, Clifton DA. Interpretable machine learning-based decision support for prediction of antibiotic resistance for complicated urinary tract infections. NPJ Antimicrob Resist. 2023;1(1):14. https:\/\/doi.org\/10.1038\/s44259-023-00015-2.","journal-title":"NPJ Antimicrob Resist"},{"issue":"7","key":"1441_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00063-21","volume":"65","author":"RJ McGuire","year":"2021","unstructured":"McGuire RJ, Yu SC, Payne PRO, Lai AM, Vazquez-Guillamet MC, Kollef MH, et al. A pragmatic machine learning model to predict carbapenem resistance. Antimicrob Agents Chemother. 2021;65(7):e0006321. https:\/\/doi.org\/10.1128\/AAC.00063-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1441_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-023-01326-9","volume":"12","author":"Y Dai","year":"2023","unstructured":"Dai Y, Zhang L, Pan T, et al. The ICU-CARB score: a novel clinical scoring system to predict carbapenem-resistant gram-negative bacteria carriage in critically ill patients upon ICU admission. Antimicrob Resist Infect Control. 2023;12:118. https:\/\/doi.org\/10.1186\/s13756-023-01326-9.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1441_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-024-01509-y","volume":"13","author":"T Wu","year":"2024","unstructured":"Wu T, Wang X, Shen Z, et al. External validation of the ICU-CARB score to predict carbapenem-resistant gram-negative bacteria carriage in critically ill patients upon ICU admission: a multicenter analysis. Antimicrob Resist Infect Control. 2024;13:150. https:\/\/doi.org\/10.1186\/s13756-024-01509-y.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"1441_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106388","volume":"90","author":"K Yuan","year":"2025","unstructured":"Yuan K, Luk A, Wei J, Walker AS, Zhu T, Eyre DW. Machine learning and clinician predictions of antibiotic resistance in Enterobacterales bloodstream infections. J Infect. 2025;90(2):106388. https:\/\/doi.org\/10.1016\/j.jinf.2024.106388.","journal-title":"J Infect"},{"key":"1441_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"key":"1441_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","volume":"388","author":"KGM Moons","year":"2025","unstructured":"Moons KGM, Damen JAA, Kaul T, Hooft L, Andaur Navarro C, Dhiman P, et al. PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods. BMJ. 2025;388:e082505. https:\/\/doi.org\/10.1136\/bmj-2024-082505.","journal-title":"BMJ"},{"key":"1441_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2019","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. 2nd ed. Cham: Springer; 2019. https:\/\/doi.org\/10.1007\/978-3-030-16399-0.","edition":"2nd ed"},{"issue":"1","key":"1441_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1466-7","volume":"17","author":"B Van Calster","year":"2019","unstructured":"Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW, Topic Group \u2018Evaluating diagnostic tests and prediction models\u2019 of the STRATOS initiative. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230. https:\/\/doi.org\/10.1186\/s12916-019-1466-7.","journal-title":"BMC Med"},{"key":"1441_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6","volume":"352","author":"AJ Vickers","year":"2016","unstructured":"Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests. BMJ. 2016;352:i6. https:\/\/doi.org\/10.1136\/bmj.i6.","journal-title":"BMJ"},{"key":"1441_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2020.12.021","volume":"131","author":"MJL Bours","year":"2021","unstructured":"Bours MJL. Bayes\u2019 rule in diagnosis. J Clin Epidemiol. 2021;131:158\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.12.021.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1441_CR16","first-page":"203","volume":"19","author":"AM \u0160imundi\u0107","year":"2009","unstructured":"\u0160imundi\u0107 AM. Measures of diagnostic accuracy: basic definitions. EJIFCC. 2009;19(4):203\u201311.","journal-title":"EJIFCC"},{"key":"1441_CR17","doi-asserted-by":"publisher","DOI":"10.5061\/dryad.7sqv9s55x","author":"LN Cooper","year":"2025","unstructured":"Cooper LN, Johnson AO, Powell S, Dennis CR, Hanna JJ, Medford RJ. Antimicrobial Resistance Microbiological Dataset (ARMD-ECUH): a deidentified collection of electronic health records from a rural academic health system for antimicrobial resistance research. 2025. Dryad. https:\/\/doi.org\/10.5061\/dryad.7sqv9s55x.","journal-title":"Dryad"},{"key":"1441_CR18","doi-asserted-by":"publisher","DOI":"10.5061\/dryad.0rxwdbsd5","author":"LN Cooper","year":"2025","unstructured":"Cooper LN, Beauchamp AM, Diaz MI, et al. Antimicrobial Resistance Microbiological Dataset (ARMD-UTSW): a deidentified collection of electronic health records, from a quaternary, academic medical center, for antimicrobial resistance research. 2025. Dryad. https:\/\/doi.org\/10.5061\/dryad.0rxwdbsd5.","journal-title":"Dryad"},{"key":"1441_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/s41597-025-05649-7","volume":"12","author":"F Nateghi Haredasht","year":"2025","unstructured":"Nateghi Haredasht F, Amrollahi F, Maddali MV, et al. Antibiotic Resistance Microbiology Dataset (ARMD): a resource for antimicrobial resistance from EHRs. Sci Data. 2025;12:1299. https:\/\/doi.org\/10.1038\/s41597-025-05649-7.","journal-title":"Sci Data"},{"key":"1441_CR20","volume-title":"Performance standards for antimicrobial susceptibility testing. 36th ed. CLSI supplement M100","author":"Clinical and Laboratory Standards Institute","year":"2026","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 36th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2026."},{"key":"1441_CR21","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Definitions of S, I and R. EUCAST. https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/definition-of-s-i-and-r\/. Accessed 22 Jul 2026"},{"issue":"1","key":"1441_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1175\/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2","volume":"78","author":"GW Brier","year":"1950","unstructured":"Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev. 1950;78(1):1\u20133. https:\/\/doi.org\/10.1175\/1520-0493(1950)078%3c0001:VOFEIT%3e2.0.CO;2.","journal-title":"Mon Weather Rev"},{"issue":"6","key":"1441_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565\u201374. https:\/\/doi.org\/10.1177\/0272989X06295361.","journal-title":"Med Decis Making"},{"key":"1441_CR24","first-page":"4765","volume":"30","author":"SM Lundberg","year":"2017","unstructured":"Lundberg SM, Lee SI. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;30:4765\u201374.","journal-title":"Adv Neural Inf Process Syst"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01441-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01441-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:03:00Z","timestamp":1791954180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01441-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1441"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01441-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"27 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Daniele Roberto Giacobbe is an Advisory Board member and Matteo Bassetti is an Editorial Board member of Infectious Diseases and Therapy. Daniele Roberto Giacobbe and Matteo Bassetti were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Outside the submitted work, Matteo Bassetti has received funding for scientific advisory boards, travel, and speaker honoraria from Cidara, Gilead, Menarini, MSD, Mundipharma, Pfizer, and Shionogi. Outside the submitted work, Daniele Roberto Giacobbe reports investigator-initiated grants from Pfizer, Shionogi, Menarini, Tillotts Pharma, Advanz Pharma, bioM\u00e9rieux, and Gilead Italia, travel support from Pfizer, bioM\u00e9rieux, and Shionogi, and speaker\/advisor fees from Pfizer, bioM\u00e9rieux, Advanz Pharma, Shionogi, Menarini, and Tillotts Pharma. Outside the submitted work, Antonio Vena reports personal fees for speaker\/advisor from Pfizer Inc, Shionogi, Tillotts Pharma, Menarini, Gilead Italia, Mundipharma, Advanz Pharma and MSD. Emmanuel Pio Pastore reports no conflicts of interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available, de-identified secondary data and was exempt from ethics committee approval.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}